choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Neulasta

Neulasta Newsletter
  • FDA Approves Lupin’s Pegfilgrastim Biosimilar, ARMLUPEG 10 Dec 2025 00:11 GMT

    … syringe presentation, referencing Amgen’s NEULASTA.  ARMLUPEG is indicated to decrease … are receiving myelosuppressive anti-cancer drugs and to increase survival rates … are currently six other FDA-approved biosimilars referencing NEULASTA: Biocon’s FULPHILA …

  • <![CDATA[Neulasta Biosimilar Armlupeg FDA Approved to Prevent Infection ]]> 02 Dec 2025 03:22 GMT

    … Cyrus Karkaria, president, biotechnology, Lupin, said in … pharmaceutical company that develops branded and generic medicines … , 2022 – FDA Approves Fylnetra Neulasta Biosimilar Fylnetra ( … receiving myelosuppressive cancer treatment associated with …

  • Lupin Wins FDA Approval for Armlupeg Pegfilgrastim Biosimilar 02 Dec 2025 12:40 GMT

    … drug Neulasta®. The approval marks a significant step in the Indian pharmaceutical … complications of cancer treatment, often requiring hospitalization … affordable, high-quality medicines to U.S. … Karkaria, President of Biotechnology at Lupin, called …

  • <![CDATA[FDA Approves Pegfilgrastim-unne for Nonmyeloid Cancers, Febrile Neutropenia]]> 02 Dec 2025 04:49 GMT

    … undergoing treatment with myelosuppressive anticancer drugs linked … biosimilar to pegfilgrastim (Neulasta). Pegfilgrastim is used … more affordable, accessible medicines to US patients. … FDA approves Lupin’s Armlupeg injection. News release. Pharmaceutical …

  • Lupin Receives Approval from U.S. FDA for Biosimilar Armlupeg - Pegfilgrastim-unne 01 Dec 2025 10:43 GMT

    … Food and Drug Administration (U.S. FDA) has approved … reducing barriers to treatment and empowering patients … . Cyrus Karkaria, President, Biotechnology, Lupin. Pegfilgrastim 6 mg … Bulls Keywords Lupin INE326A01037 Pharmaceuticals USFDA Approval Armlupeg …

  • Lupin gets U.S. FDA nod for biosimilar 01 Dec 2025 21:59 GMT

    … mL injection as biosimilar to Neulasta (pegfilgrastim) 6 mg… biotech facility in Pune, which was inspected by the U.S. FDA … providing more affordable, accessible medicines to U.S. patients. … receiving myelosuppressive anti-cancer drugs associated with a …

  • Lupin gets FDA nod for white blood cell booster Neulasta Biosimilar 01 Dec 2025 12:41 GMT

    … Limited has secured US FDA approval for Neulasta (Pegfilgrastim-unne) … doses of radiation The drug also helps to decrease … receiving myelosuppressive anti-cancer drugs. As of September this … providing more affordable, accessible medicines to U.S. patients. …

  • US FDA approves Lupin’s Armlupeg injection 01 Dec 2025 10:37 GMT

    … Neulasta (pegfilgrastim). The company will manufacture the product at its biotechnology … undergoing treatment with myelosuppressive anti-cancer drugs … more affordable, accessible medicines to US patients … deserve! The Pharmaceutical Technology Excellence Awards …

  • Drug Maker Lupin Receives Approval From The US Health Regulator For A Biosimilar Indicated For Neutropenia Treatment In Cancer Patients 01 Dec 2025 07:27 GMT

    … treatment of neutropenia in cancer patients.The US Food and Drug … prefilled syringe, as biosimilar to Neulasta (pegfilgrastim) injection, the … the company's biotech facility in Pune, which … providing more affordable, accessible medicines to the US patients. …

  • Lupin gets U.S. FDA Approval for Biosimilar Armlupeg 01 Dec 2025 03:54 GMT

    … . FDA clearing its new product Armlupeg™, a biosimilar version of Neulasta … . The drug will be manufactured at Lupin’s biotech facility in … strong due to rising cancer treatment volumes. Armlupeg™ is designed … cost efficiencies and expanded treatment access.

Satisfied with the content?

Continue to create your account.